Data justify further research on potential of psychedelics in treating psychiatric disorders

Summary

Psilocybin and MDMA, powerful psychedelics, are showing significant promise for psychiatric medicine. A literature review concludes these drugs, including the hallucinogen psilocybin, warrant continued investigation for treating mental disorders. Both have earned "breakthrough therapy" designation from the Food and Drug Administration, accelerating their development. Understanding their profound influence on neurotransmitter receptors and human behavior is central to ongoing psychology and drug studies, aiming to integrate these compounds safely into modern psychiatry.

Abstract

Although research findings to date do not support the use of psychedelic compounds in the treatment of psychiatric disorders, the existing body of research justifies continued investigation, a literature review concludes. The review found the most significant evidence supporting use of psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA). Both of these drugs have been given “breakthrough therapy” designation by the Food and Drug Administration (FDA), which is intended to expedite the evaluation and development of drug candidates that might offer significant advantages over existing treatments for serious illnesses.

Tags